Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
All news
Biotechnology
Gilead Sciences has announced new positive safety data on Vemlidy (tenofovir alafenamide) at The Liver Meeting 2019 in Boston, USA. 8 November 2019
Biotechnology
US biopharma firm Aimmune Therapeutics, which is developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy (OIT) for food allergies, such as peanut allergy, into clinical practice is comparable to those for subcutaneous immunotherapy (SCIT) for environmental allergies. 8 November 2019
Biotechnology
A new drug application has been filed with the Japanese Ministry of Health, Labor and Welfare (MHLW) for satralizumab (development code: SA237), an anti-interleukin-6 (IL-6) receptor humanized recycling antibody, for the treatment of neuromyelitis optica spectrum disorder (NMOSD). 8 November 2019
Biotechnology
Swiss pharma giant Roche has discontinued a Phase II/III trial of RG6206, an anti-myostatin adnectin, after a futility analysis showed that the drug was “highly unlikely” to demonstrate clinical benefit in patients with Duchenne muscular dystrophy (DMD). 8 November 2019
Biotechnology
New details from the Phase III OLYMPUS and ROCKIES trials show that roxadustat significantly increased hemoglobin (Hb) levels in certain people with anemia from chronic kidney disease (CKD). 8 November 2019
Biotechnology
The US Department of Health and Human Services (HHS) has filed a patent infringement lawsuit against Californian biotech major Gilead Sciences. 7 November 2019
Biotechnology
Janssen, the pharmaceutical arm of American drugmaker Johnson & Johnson, has applied for European approval for its investigational Ebola vaccine regimen. 7 November 2019
Biotechnology
Denmark-based allergy specialist ALK-Abelló reported that revenues had risen by 11% in local currencies as the company presented its third-quarter results. 7 November 2019
Biotechnology
Taking advantage of a captive audience at the 17th European AIDS Conference (EACS) in Basel, Switzerland, US biotech major Gilead Sciences today released positive data on two of its newer antiviral treatments. 6 November 2019
Biotechnology
Japan’s Takeda Pharmaceutical and the MD Anderson Cancer Center have launched a collaboration to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies. 6 November 2019
Biotechnology
US biotech Regeneron Pharmaceuticals and Vyriad, a company formed in 2016 through the merger of Omnis Pharma an Magnis Therapeutics, today announced a research collaboration and option licensing agreement focused on the development of new oncolytic (cancer-killing) virus-based treatments for various forms of cancer. 6 November 2019
Biotechnology
A new London-based cancer vaccine and immunotherapy company, Ervaxx, has launched following two years in incubation. 6 November 2019
Biotechnology
UK-headquartered Artios Pharma has in-licensed a small-molecule ATR inhibitor program, developed jointly by the University of Texas MD Anderson Cancer Center and US venture capital firm ShangPharma. 6 November 2019
Biotechnology
Daiichi Sankyo said today it has filed a Declaratory Judgement action in the District Court of Delaware in response to receiving communications from Seattle Genetics with respect to a collaboration between the two companies from 2008 to 2015 for the development of antibody-drug conjugates (ADCs). 5 November 2019
Biotechnology
Shares in US company Aveo Oncology lost more than 30% of their value on Monday after another setback affecting the firm’s lead product. 5 November 2019
Biotechnology
New York, USA-based biotech Regeneron has reported a positive third quarter revenue result, with sales up 23% to $2.05 billion, compared with the same period last year. 5 November 2019
Biotechnology
US biotech firm Halozyme Therapeutics today announced that the HALO-301 Phase III clinical study evaluating its investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to reach the primary endpoint of overall survival. 4 November 2019
Biotechnology
US therapeutic gene editing company Sangamo Therapeutics has appointed Sung Lee as executive vice president and chief financial officer, effective October 31, 2019. Mr Lee oversees finance, facilities and information technology functions for Sangamo and reports to the firm’s chief executive. 2 November 2019
Biotechnology
USA-based biotech Ovid Therapeutics has made two senior leadership changes to further build the company’s capabilities as it approaches top-line results from the pivotal Phase III NEPTUNE trial for OV101 in Angelman syndrome, expected in mid-2020. 2 November 2019
Biotechnology
US drugmaker Vertex Pharmaceuticals saw progress with its triple-combination cystic fibrosis treatment on two fronts on Thursday. 1 November 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze